Thanks for clarifying RVXoldtimer. 

Just as a reminder to folks about the Royalty Preferred Shares.....from the Nov 2016 Management Information Circular:

"The Royalty Preferred Shares entitle Zenith to cumulative preferential dividends in an amount ranging from 6% to 12% of Net Apo Revenue during any year, subject to an adjustment for tax payable on the dividend. The dividend amount is calculated based on 6% of Net Apo Revenue of up to US$1 billion, 8% of Net Apo Revenue of between US$1 billion and US$2 billion, 10% of Net Apo Revenue between US$2 billion and US$5 billion and 12% of Net Apo Revenue in excess of US$5 billion."

This original arrangement above was amended in 2016 to remove the Apo-AI requirement:

"The terms of the Royalty Preferred Shares currently entitle the holder of the Royalty Preferred Shares to a dividend calculated based on a percentage of net revenue earned by the Corporation from the sale or licensing of products or intellectual property rights that increase the plasma levels of ApoA-1, a component of the complex of lipids and proteins that are associated with a decreased risk of atherosclerosis and coronary heart disease.

As indicated above, detailed study of the results of the Corporation’s clinical trial program indicates that apabetalone/RVX-208 has been shown to affect expression of numerous targets important for cardiovascular disease and ApoA-1 is only one of these targets. Therefore, the Corporation has determined that it is necessary to amend the terms of the Royalty Preferred Shares to remove the requirement that the pharmaceutical agent elevate plasma levels of ApoA-1."